(Date:12/2/2009)...r patients who have a prostate-specific antigen (P...s after external beam radiation therapy (EBRT) are...r-related death, according to a study in the Decem...ion Oncology*Biology*Physics, the official journal...STRO)., PSA levels in a prostate cancer patient ...
(Date:12/2/2009)... Constraint-induced movement therapy (CIMT) is a ...ldren with hemiplegic cerebral palsy, but more res...iew published in the November issue of Physical T...can Physical Therapy Association (APTA). The revie...stematic reviews, concluded that further research ...
(Date:12/2/2009)... AB First Aid has been a top name in the ...80. With quality products, professional staff, and...pplies, AB First Aid has established itself as a p... care, and as a first aid supplies distributor. Th... about to enter into its next phase with the redes...
(Date:12/2/2009)... National Race Series to increase awarene...milies on the importance of early detection , ..., 2009 -- Men, women, families, friends and neighb...ted to participate in the Rudolph Ramble 5K. The ...Race Series , which was launched by the Prostate ...
(Date:12/2/2009)... A team of Kendall Hunt authors earned th...ard at the recent National Association for Gifted ...ovember 5-7, 2009. , Dubu...all Hunt authors earned the 2009 Gifted Child Quar...al Association for Gifted Children’s annual ...
Breaking Medicine News(10 mins):Health News:PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients 2Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 3Health News:PACE Race Returns with Denver's Rudolph Ramble 2Health News:PACE Race Returns with Denver's Rudolph Ramble 3Health News:PACE Race Returns with Denver's Rudolph Ramble 4Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2...sexual behaviors strongly influences Latina womens...researchers from the University of Chicago Medical...olescent Health. , Greater sense of personal cont...t sexual intercourse may outweigh the influence of...
...of hormone therapy, study finds , , WEDNES...mone replacement therapy raise the risk of breast ...he risk of a specific type of malignancy: lobular ... that the cancer risk appeared earlier than the fi...
... be the largest comparison of blood samples collec...ophrenia suggest that infection with the common To... animals, may increase the risk of schizophrenia. ...ns Center appears in the January issue of the Amer...
...t this release there are hypnotic suggestions abou...top one? Would you be able to pick out the suggest...it and despite what else is going on in the news, ...published book Breathe, Freedom: Kicking the Crap ...
.... Marlies Van Hoef,CEO of Transplant Creations ( h...vestment community in an all-new interview with h...view include an overview of the company, recent,pr...te at, http://www.transplantcreations.com or go t...
...urn-Key Solution for Health Portal ...16 HealthCare.com,( http://www.healthcare.com ), ...ne health destination, today announced that it has...companies,government websites, and online media si...
Other Medicine News:Health News:Sense of personal control influences Latinas' decisions about sexual debut 2Health News:HRT Raises Risk of Lobular Breast Cancer 2Health News:HRT Raises Risk of Lobular Breast Cancer 3Health News:Toxoplasma infection increases risk of schizophrenia, study suggests 2Health News:Hypnotist ready to kick cigarette butt 2Health News:WallSt.net Updates Investment Community Through All-New Interview With Transplant Creations 2Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 2Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 3(Date:12/2/2009)..., NEW YORK, Dec. 2 Reportlinker...s available in its catalogue: ,, Hepatitis C V...Trends & Opportunities ,, http://www.repo...eutics---A-Global-Update-of-Market-Trends--Opportu... all these years of meager clinical outcomes owing...
(Date:12/2/2009)...BBOTT PARK, Ill., Dec. 2 ...terizing a vast array of microorganisms has been n...ientist magazine. A panel of expert judges evalu... determine the year,s top innovations, with the wi... and online at www.the-scien t ist.com/top10in...
(Date:12/2/2009)...EW YORK, Dec. 2 With the addition ...s, led by Neil H. Ekblom, LeClairRyan,s medical ma...ed its reach in the New York market. Mr. Ekblom, a...ce in defending ophthalmology-related malpractice ...g group of medical malpractice defense attorneys l...
Breaking Medicine Technology:Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 8Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist 2Neil H. Ekblom and Medical Malpractice Defense Team Join LeClairRyan 2Neil H. Ekblom and Medical Malpractice Defense Team Join LeClairRyan 3Curemark Closes Series A Financing 4839 1Curemark Closes Series A Financing 4839 2Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 1Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 2Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 3Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 4Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 5Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 6Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 7Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 8Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 9Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 10Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 11Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 12Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 13Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results 54024 14OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX 011 13466 1OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX 011 13466 2OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX 011 13466 3...NKTR-102 Associated With Increased and Sustained ...e of Irinotecan, SAN FRANCISCO, Oct. 25 Nektar T...eclinical data today on its proprietary,product ca...EORTC,International Conference in San Francisco, C...tumor activity and unique pharmacokinetic profile ...
... WEST HAVEN, Conn., Oct. 25 ,Today Bayer announced...ers,regarding the use of Trasylol(R) (aprotinin in... loss and blood transfusion undergoing coronary,ar...ary bypass (CPB). The company did so after being ...ted the Canadian-based trial -- a randomized, cont...
Other Medicine Technology:NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 2NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 3NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 4NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models 5Bayer Issues Additional Guidance to Physicians on Trasylol(R) 2Bayer Issues Additional Guidance to Physicians on Trasylol(R) 3Bayer Issues Additional Guidance to Physicians on Trasylol(R) 4Bayer Issues Additional Guidance to Physicians on Trasylol(R) 5...absystems was designed specifically to combine erg... features such as the new fast dial system with .0... define this as a new leader in single channel pip... a custom fit for different hand sizes. The new sh...
Eppendorf Research Series 2100 Adjustable-volume Pipette, 10-100 l
...absystems was designed specifically to combine erg... features such as the new fast dial system with .0... define this as a new leader in single channel pip... a custom fit for different hand sizes. The new sh...
Micropipet, adjustable volume, 2-20 microliter
Medicine Products: